AbbVie Inc.'s (NYSE:ABBV) stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast.

The company reported an adjusted EPS of $2.46 on Friday, up 6.5% year over year and beating the consensus of $2.38.

The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the consensus of $12.92 billion.

It reported adjusted earnings per share of $2.46, beating the street view of $2.38.

Also Read: AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now

Global net revenues from the immunology portfolio were $6.26 billion, up 16.6% (+18.1% on an operational basis).

• Skyrizi sales increased 70.5% (+72%) to $3.425 billion.
• Rinvoq sales reached $1.72 billion, an increase of 57.2% (+59.7%).
• Humira sales fell 50.6% (-49.5%) to $1.12 billion.

Oncology portfolio generated sales of $1.633 billion, up 5.8% (+7.5%).

• Imbruvica's net revenues were $738 million, down 11.9%.
• Venclexta's revenues were $665 million, up 8.3% (+12.3%).
• Elahere revenues were $179 million.

Neuroscience portfolio sales were $2.282 billion, up 16.1% (+17%).

• Vraylar net revenues were $765 million, up 10.3%.
• Botox Therapeutic's net revenues were $866 million, up 15.8% (+17%).
• Ubrelvy and Qulipta's net revenues were $240 million and $193 million, respectively.

Aesthetics sales were $1.102 billion, down 11.7% (-10.2%).

• Botox Cosmetic sales decreased 12.3% (-10.7%) to $556 million.
• Juvederm sales fell 22.2% (-20%) to $231 million.

"AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year," said Robert Michael, CEO of AbbVie. "The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term."

Outlook: AbbVie raised the fiscal year 2025 adjusted EPS from $11.99-$12.19 to $12.09-$12.29 compared to the consensus of $12.17.

In January, AbbVie reaffirmed its forecast of high single-digit average annual revenue growth through 2029, using 2024 as the starting point for that calculation.

• The company also raised its long-term sales outlook for its immunology drugs, Skyrizi and Rinvoq. AbbVie expects the two drugs to bring in more than $31 billion in 2027—about $4 billion more than its previous estimate. That includes over $20 billion from Skyrizi and over $11 billion from Rinvoq.

Additionally, AbbVie updated its expectations for its aesthetics business, now projecting high single-digit average annual growth through 2029, starting from 2025.

William Blair writes, "Investors will be looking for greater clarity on the potential impacts of pharmaceutical tariffs on AbbVie's key brands, and the aesthetics business could face greater headwinds from macroeconomic uncertainty, but we continue to believe AbbVie has one of the cleanest revenue growth stories in the biopharma space over the next five years."

Analyst Matt Phipps maintains the Outperform rating.

Price Action: ABBV stock is trading higher by 1.13% at $182.41 at the last check Friday.

Read Next:

• West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag

Photo via Shutterstock